Home / Market News / $FMS
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

JPMorgan Maintains Underweight Rating on Fresenius Medical Care

Oct 23, 2026, 12:04 PM UTC · Primary ticker $FMS

JPMorgan analyst David Adlington maintained an 'Underweight' rating on Fresenius Medical Care with a 32.30 euros price target. The bank noted that consensus estimates for the company's quarterly results have not increased as anticipated, despite potential headwinds from US treatment reimbursement costs in Q4.

JPMorgan maintained its 'Underweight' rating on Fresenius Medical Care, citing concerns that consensus estimates for the company's quarterly results have not risen as expected. This is particularly relevant given potential headwinds from US treatment reimbursement costs in the fourth quarter, which could negatively impact the dialysis provider's profitability. For traders, this signals a cautious outlook on FMS's short-term performance, suggesting potential downside risk or limited upside. The long-term implications depend on how the company navigates these reimbursement challenges and whether it can meet or exceed revised expectations.

$FMS negative Underweight rating maintained due to headwinds
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.